German drugmaker BioNTech acquires London-based AI startup InstaDeep for up to £562M to help harness machine learning to improve drug discovery
Covid-19 vaccine maker is looking to use machine learning to help discover new treatments — BioNTech has agreed to buy UK artificial intelligence start …
Context & Ripple Effects
BioNTech is converting its Covid-vaccine windfall into an acquisition: instead of licensing machine-learning tools the way peers have, it is buying a London-based AI company outright for up to £562M. The move lands in a market where deal structures are still being sorted out — AstraZeneca chose a partnership worth up to $247M with Absci (AstraZeneca's Absci deal) just months before this, while DeepMind spinout Isomorphic Labs struck upfront-plus-milestone partnerships with Eli Lilly and Novartis (Isomorphic Labs' pharma partnerships).
The London angle matters too: InstaDeep joins BenevolentAI (BenevolentAI's $2.1B valuation round) as UK-built drug-discovery AI drawing global pharma money, consistent with Dealroom's finding that London has overtaken Paris as Europe's leading tech hub. The question this deal answers is whether pharma incumbents will rent AI capability or own it.
First-order effects
- BioNTech gains in-house machine-learning capacity for drug discovery, reducing its dependence on external AI vendors as it diversifies beyond Covid-vaccine revenue.
- InstaDeep's London team and technology are absorbed into a German pharmaceutical group, removing one of Europe's more prominent independent AI-for-drug-discovery startups from the standalone market.
Second-order effects
- Rivals that partnered rather than bought — AstraZeneca with Absci, Eli Lilly and Novartis with Isomorphic Labs — now face a peer that owns its AI stack outright, pressuring them toward deeper equity stakes or acquisitions of their own.
- Acquisition exits at nine-figure sums strengthen the fundraising case for remaining independents like Isomorphic Labs, whose subsequent $600M raise (Isomorphic Labs' $600M raise) shows investors pricing in exactly this kind of strategic demand.
Third-order effects
- If ownership beats licensing as the pattern holds, AI drug-discovery firms bifurcate into acquired subsidiaries of pharma groups and a shrinking set of independent platforms, reshaping who captures the value when an algorithm finds a drug.
- London's position as Europe's top tech hub gives UK AI startups a credible path to pharma-scale exits, potentially pulling more biopharma M&A through the city rather than US hubs.
The trend: Big pharma is moving from renting AI drug-discovery capability through partnerships to owning it outright via acquisitions, with BioNTech's InstaDeep buy marking the shift from license deals to balance-sheet bets.